INTRODUCTION
============

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases ([@r1]). The most important risk factor for COPD is cigarette smoking. Adults who have a history of more than 40 pack years of smoking show an approximately twelve-fold higher positive likelihood ratio for airflow obstruction ([@r2]). Other risk factors may include environmental exposures other than smoking, atopy, and antioxidant deficiency. The estimated worldwide prevalence of COPD is 7.5% to 10% ([@r3]).

According to the 2008 Korean National Health and Nutrition Examination Survey-IV, 13.4% of the population aged over 40 years in Korea had spirometrically-detected airflow obstruction consistent with COPD ([@r4]) and approximately 90% of them were classified as patients with early COPD. Even as a higher prevalence of COPD has been reported, the disease remains under-diagnosed, and it is believed that most patients with COPD here are under treated ([@r4]). One study reported that approximately 62% of moderate to severe COPD patients have variability in symptoms, which could precede potentially fatal delays ([@r5]) in diagnosis and treatment. The prognosis for patients with COPD can improve greatly if it is diagnosed in its early stages and promptly addressed with medications and lifestyle changes (including smoking cessation and regular exercise) aimed at preventing disease progression ([@r6]). However, in Korea, studies regarding the contribution of early detection and treatment to prevention of COPD progression have been scarce. Thus, the KOrea COpd Subgroup Study team (KOCOSS) cohort was developed to address the above issues through the serial observation of disease progression and outcomes, to identify risk factors that will form a foundation for early detection of COPD patients who may be at higher risk of progression, and to provide guidance for further studies. We present herein a cross-sectional analysis of the data collected at the time of enrollment in KOCOSS to describe the baseline characteristics of the KOCOSS cohort.

MATERIALS AND METHODS
=====================

Data collection
---------------

Recruitment and measurement occurred between December 2011 and October 2014. There are 45 study centers throughout Korea (Seoul, Pusan, Daegu, Incheon, Chungcheong-do, Gyeonggi-do, Gangwon-do, Gyeongsang-do, and Jeju-do) that are enrolling patients. Inclusion criteria are diagnosis of COPD by a pulmonologist, age ≥ 40 years, symptoms including cough, sputum, dyspnea, and post-bronchodilator forced expiratory volume in one second (FEV~1~)/forced vital capacity (FVC) of 70% less than normal predicted value. The medical history at the first visit included frequency and severity of exacerbations in the previous 12 months, smoking status, patient-reported education level, medications, including those already prescribed for COPD, and comorbidities. For diagnosis of depression, we used Beck Depression Inventory (BDI), which confirmed of its validity and reliability ([@r7]). The medical research council (mMRC) dyspnea score was recorded, as were results of the COPD assessment test (CAT) and the COPD-specific version of St. George's Respiratory Questionnaire (SGRQ-C). A 6-minute walk distance (6MWD) test was also performed. All of the data were reported using case-report forms (CRFs) completed by physicians or trained nurses, and patients were to be evaluated at regular 6-month intervals after the initial examination. The initial data sets were analyzed to identify the baseline patient characteristics that are reported in this study. Major exclusion criteria were asthma, other obstructive lung diseases including bronchiectasis, tuberculosis destroyed lung, inability to complete pulmonary function test, myocardial infarction or cerebrovascular event within the previous 3 months, pregnancy, rheumatoid disease, malignancy, irritable bowel disease, and steroid use for conditions other than COPD exacerbation within 8 weeks before enrollment. Exacerbations were defined as worsening of any respiratory symptom, such as increased sputum volume, purulence, or increased dyspnea, which required treatment with systemic corticosteroids, antibiotics, or both.

Pulmonary function, disease severity, and exercise assessment
-------------------------------------------------------------

Spirometry and 6MWD were performed according to standard techniques ([@r8],[@r9]). COPD severity was categorized by spirometry alone, in accordance with the 2007 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Stage I COPD was present at FEV~1~ ≥ 80% predicted, stage II at FEV~1~ ≤ 50% to 80% predicted, stage III at FEV~1~ ≤ 30% to 50% predicted, and stage IV at FEV~1~ \< 30% predicted. In addition, a risk/symptom-classification system (A to D) consistent with the 2011 GOLD guidelines was used.

Quality of life and dyspnea scores
----------------------------------

The SGRQ-C was administered to assess the health status from the patient's perspective ([@r10]). The SGRQ-C is a 14-item questionnaire that can be summarized as a total score, as well as by three component scores for symptoms, activities, and impacts. Total and component scores were calculated according to algorithms provided in the SGRQ-C instruction manual ([@r11]). Dyspnea was evaluated using the mMRC dyspnea scale, which is five-point scale with higher scores indicating more severe dyspnea. The CAT score was also used for evaluation of dyspnea. It consists of 8 items, each scored from 0 to 5, with higher scores indicating a more severe symptom ([@r12]).

Statistical analyses
--------------------

In case of continuous variables, descriptive statistics are reported as means with standard deviations, and in the case of categorical variables as the number of patients per category and frequency of responses. Continuous variables with different severity classifications were analyzed using two-sample t-test and Chi-squared tests or Fisher's exact test for comparisons of categorical variables. The correlation between GOLD group A to D and symptom scores (mMRC, CAT score), SGRQ-C total score, and 6MWD test result was checked using the Spearman rank correlation coefficient (rho), because GOLD group A, B, C, D is an ordinal categorical variable. Differences were considered statistically significant at *P* \< 0.05.

Ethics statement
----------------

The protocol was approved by the institutional review board at each center (Konkuk University Chungju Hospital, IRB No. 2012-001). All of the patients provided written informed consent for participation in the study.

RESULTS
=======

Baseline patient characteristics
--------------------------------

[Table 1](#t1){ref-type="table"} shows the baseline characteristics of the COPD patients who were included in this study. Their average age was 69.9 ± 7.8 years, and the most of them were male (n = 872, 91.2%). Almost all patients (91.5%) were former or current smokers. Nonsmoker-COPD counted as 80 cases (8.5%). The post-bronchodilator FEV~1~ was 55.8% ± 16.7% predicted, the FEV~1~/FVC ratio was 49.0 ± 12.0, and the mean 6MWD was 365.6 ± 117.3 meter. Mean CAT and mMRC scores were 15.5 ± 7.7 and 1.6 ± 1.0. The CAT score was ≥ 10 in 76.7% of the patients and the mMRC score was ≥ 2 in 45.8% of the patients. The total SGRQ-C score was 34.8 ± 19.6. The mean number of acute exacerbations during one year before enrollment was 0.6 ± 1.6. Of the total study population, the percentage in GOLD stage I, II, III, and IV was 5.6 (n = 51), 56.9 (n = 520), 31.8 (n = 291), and 5.7 (n = 52) and the percentage in GOLD group A, B, C, and D was 12.8 (n = 122), 42.0 (n = 399), 5.1 (n = 48), and 36.9 (n = 351).

###### Baseline characteristics of the KOCOSS subjects
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  Variables                                                    No. of subjects   No. (%) or observation
  ------------------------------------------------------------ ----------------- ------------------------
  Age (yr, mean ± SD)                                          956               69.9 ± 7.8
  Male, No. (%)                                                956               872 (91.2)
  BMI (kg/m^2^, mean ± SD)                                     926               22.7 ± 3.4
  Smoking, pack/yr, (mean ± SD)                                812               43.9 ± 25.1
   Current smoker (%)                                          938               262 (27.9)
   Former smoker (%)                                           596 (63.5)        
   Non -- smoker (%)                                           80 (8.5)          
  Number of acute exacerbation during one year before enroll   942               
   Mean number (mean ± SD)                                     0.58 ± 1.6        
   0 (%)                                                       692 (73.5)        
   1 (%)                                                       145 (15.4)        
   ≥ 2 (%)                                                     105 (11.2)        
  Number of comorbidities (mean ± SD)                          958               1.7 ± 1.4
   0                                                           208 (21.7)        
   1                                                           256 (26.7)        
   2                                                           258 (26.9)        
   3                                                           145 (15.1)        
   4                                                           51 (55.3)         
   5                                                           28 (2.92)         
   6                                                           7 (0.7)           
   7                                                           5 (0.5)           
  Education level                                              945               
   Middle school and below                                     540 (57.1)        
   High school                                                 280 (29.6)        
   College and above                                           125 (13.2)        
  Lung function                                                                  
   FEV~1~/FVC (%, mean ± SD)                                   916               49.0 ± 12.0
   Post bronchodilator FEV~1~ (%, mean ± SD)                   914               55.8 ± 16.7
   Post bronchodilator FEV~1~ (L, mean ± SD)                   923               1.5 ± 0.58
   FVC (L, mean ± SD)                                          923               3.06 ± 0.79
   TLC (L, mean ± SD)                                          596               5.6 ± 0.8
  6MWD (meters, mean ± SD)                                     737               365.6 ± 117.3
  Subjects requiring oxygen during/after 6MWD                  958               2 (0.3)
  Symptom scores                                               958               
   CAT (mean ± SD)                                             913               15.5 ± 7.7
    CAT score                                                  213 (23.3)        
    CAT score ≥ 10                                             700 (76.7)        
   mMRC score (mean ± SD)                                      951               1.6 ± 1.0
    mMRC score                                                 515 (54.2)        
    mMRC score ≥ 2                                             436 (45.8)        
  Questionnaire (SGRQ-C)                                                         
   Symptom                                                     947               44.2 ± 20.9
   Activity                                                    946               46.0± 27.3
   Impact                                                      947               25.7 ± 23.3
   Total                                                       944               34.8 ± 19.6
  GOLD stage (I to IV)                                         914               
   I                                                           51 (5.6)          
   II                                                          520 (56.9)        
   III                                                         291 (31.8)        
   IV                                                          52 (5.7)          
  GOLD (A to D)                                                920               
   A                                                           122 (12.8)        
   B                                                           399 (42.0)        
   C                                                           48 (5.1)          
   D                                                           351 (36.9)        

SD, standard deviation; BMI, body mass index; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; TLC, total lung capacity; 6MWD, six minutes walk distance test; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnea scale; SGRQ-C, St. George's respiratory questionnaire; GOLD, global initiative for chronic obstructive lung disease.

[Fig. 1](#f1){ref-type="fig"} shows the cumulative distribution of each GOLD (2011) group within each GOLD (2007) stage. GOLD group B patients comprised a large proportion (62.7%) compared to group A (31.4%) in the GOLD stage II patients. Similarly, GOLD stages III and IV included more patients from group D than group C (88.3 vs. 11.7 in stage III and 98.1% vs. 1.9% in stage IV). As specified in the GOLD guideline, stages III and IV do not include patients from group A or group B.

![Distribution of subjects according to the GOLD classification.](jkms-31-553-g001){#f1}

Correlation of baseline characteristics and disease severity (global initiative for chronic obstructive lung disease criteria)
------------------------------------------------------------------------------------------------------------------------------

When patients were classified according to the 2007 GOLD classification, those with early stage (I and II) COPD had fewer exacerbations (mean number of exacerbations, 0.4 vs. 0.9, *P* \< 0.001), significantly lower CAT, mMRC, and SGRQ-C total scores (13.9 vs. 18.3; 1.4 vs. 2.0; 30.4 vs. 42.9, respectively, all *P* \< 0.001), and higher BMI (23.4 vs. 21.6), post-bronchodilator FEV~1~% (66.0 vs. 38.9), 6MWD (375.9 vs. 344.2), and education levels compared to patients with advanced (stage III and IV) COPD (all *P* \< 0.001). According to the GOLD revision (2011), patients in group A and B had fewer exacerbations (mean number of exacerbations 0.1 vs. 1.2, *P* \< 0.001), significantly lower CAT (13.5 vs. 18.1), mMRC (1.3 vs. 1.9), and SGRQ-C total score (29.1 vs. 42.6), and higher BMI (23.4 vs. 21.8), post bronchodilator FEV~1~% (66.2 vs. 41.6), 6MWD (376.4 vs. 350.0 meter), and education level compared patients in groups C and D (all *P* \< 0.001) ([Table 2](#t2){ref-type="table"}).

###### Baseline characteristics of the subjects according to the GOLD stage (I + II vs. III + IV) and GOLD group (A + B vs. C + D)
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  Parameters                                                   Stage I + II   Stage III + IV   *P* value    Grade A + B     Grade C + D   *P* value                                         
  ------------------------------------------------------------ -------------- ---------------- ------------ --------------- ------------- ----------- --------------- ----- --------------- ----------
  Age (yr, mean ± SD)                                          569            69.8 ± 7.8       343          70.0 ± 7.9      0.828         520         69.7 ± 7.9      398   70.1 ± 7.8      0.550
  Male, No. (%)                                                570            516 (90.5)       342          315 (92.1)      0.417         520         474 (91.2)      398   362 (91.0)      0.917
  BMI (kg/m^2^, mean ± SD)                                     562            23.4 ± 3.3       340          21.6 ± 3.3      \< 0.001      513         23.4 ± 3.3      391   21.8 ± 3.4      \< 0.001
  Current smoker                                               567            169 (29.8)       338          82 (24.3)       0.076         519         155 (29.9)      391   98 (25.1)       0.253
  Smoking, pack/yr, (mean ± SD)                                487            43.8 ± 24.3      297          44.0 ± 26.0     0.905         447         43.5 ± 23.9     341   44.3 ± 27.0     0.649
  Number of acute exacerbation during one year before enroll   565                             340                                        521                         396                   
   Mean ± SD                                                   0.4 ± 1.6      0.9 ± 1.6        \< 0.001     0.1 ± 0.3       1.2 ± 2.3     \< 0.001                                          
   0                                                           457 (80.9)     204 (60.0)       \< 0.001     457 (87.7)      212 (53.5)    \< 0.001                                          
   1                                                           64 (11.3)      78 (22.9)                     64 (12.3)       79 (20.0)                                                       
   ≥ 2                                                         44 (7.8)       58 (17.1)                     0 (0.0)         105 (26.5)                                                      
  Number of comorbidities                                      571            1.7 ± 1.3        343          1.8 ± 1.5       0.162         521         1.6 ± 1.3       399   1.8 ± 1.5       0.082
  Education level                                              569                             343                          0.049         519                         398                   0.043
   Middle school and below                                     312 (54.8)     214 (62.4)       279 (53.8)   246 (61.8)                                                                      
   High school                                                 176 (30.9)     95 (27.7)        164 (31.6)   108 (27.1)                                                                      
   College and above                                           81 (14.2)      34 (9.9)         76(14.6)     44 (11.1)                                                                       
  Lung function                                                                                                                                                                             
   FEV~1~/FVC (%, mean ± SD)                                   570            54.5 ± 9.6       343          39.9 ± 10.0     \< 0.001      520         54.7 ± 9.7      388   41.3 ± 10.7     \< 0.001
   Post BD FEV~1~ (%, mean ± SD)                               571            66.0 ± 11.6      343          38.9 ± 7.6      \< 0.001      521         66.2 ± 11.5     387   41.6 ± 11.4     \< 0.001
   FEV~1~ (L, mean ± SD)                                       571            1.8 ± 0.5        343          1.0 ± 0.3       \< 0.001      521         1.8 ± 0.5       389   1.1 ± 0.5       \< 0.001
   FVC (L, mean ± SD)                                          571            3.3 ± 0.8        343          2.7 ± 0.7       \< 0.001      521         3.3 ± 0.8       389   2.7 ± 0.8       \< 0.001
   TLC (L, mean ± SD)                                          393            5.6 ± 0.8        193          5.6 ± 0.8       0.824         364         5.6 ± 0.8       226   5.6 ± 0.8       0.550
  6MWD (meters, mean ± SD)                                     474            375.9 ± 112.9    250          344.2 ± 120.1   \< 0.001      431         376.4 ± 110.9   294   349.8 ± 124.4   \< 0.001
  Subjects requiring oxygen during/after 6MWD                  466            2 (0.4)          242          0 (0.0)         0.549         422         2 (0.5)         286   0 (0.00)        0.518
  Symptom scores                                                                                                                                                                            
   CAT score (mean ± SD)                                       541            13.9 ± 6.9       335          18.3 ± 8.1      \< 0.001      493         13.5 ± 6.7      389   18.1 ± 8.3      \< 0.001
    CAT score                                                  151 (27.9)     51 (15.2)        \< 0.001     146 (29.6)      65 (16.7)     \< 0.001                                          
    CAT score ≥ 10                                             390 (72.1)     284 (84.8)       \< 0.001     347 (70.4)      324 (83.3)    \< 0.001                                          
   mMRC score (mean ± SD)                                      571            1.4 ± 0.9        343          2.0 ± 1.0       \< 0.001      521         1.3 ± 0.8       399   1.9 ± 1.1       \< 0.001
    mMRC score \< 2                                            367 (64.3)     122 (35.6)       \< 0.001     343 (65.8)      153 (38.4)    \< 0.001                                          
    mMRC score ≥ 2                                             204 (35.7)     221 (64.4)                    178 (34.2)      246 (61.7)                                                      
  SGRQ-C                                                                                                                                                                                    
   Symptom                                                     571            40.4 ±19.1       343          50.9 ± 21.8     \< 0.001      521         39.2 ± 18.7     398   50.7 ± 21.6     \< 0.001
   Activity                                                    570            40.3 ±23.8       343          56.7 ± 29.2     \< 0.001      520         38.9 ± 23.4     398   55.8 ± 29.3     \< 0.001
   Impact                                                      571            21.0 ±19.8       343          34.3 ± 26.2     \< 0.001      521         19.5 ± 18.7     398   34.3 ± 26.1     \< 0.001
   Total                                                       570            30.4 ± 16.5      342          42.9 ± 21.6     \< 0.001      520         29.1 ± 15.6     397   42.6 ± 21.6     \< 0.001

GOLD, global initiative for chronic obstructive lung disease; SD, standard deviation; BMI, body mass index; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; TLC, total lung capacity; 6MWD, six minutes walk distance test; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnea scale; SGRQ-C, St. George's respiratory questionnaire.

Correlation of medication history and disease severity (global initiative for chronic obstructive lung disease criteria, 2011)
------------------------------------------------------------------------------------------------------------------------------

The most commonly used medications before and after initial enrollment in the study, regardless of GOLD group, were long acting muscarinic antagonists (LAMA; Group A to D, n = 68 \[48.2%\], n = 204 \[40.6%\], n = 29 \[41.4%\], and n = 227 \[34.2\]; *P* \< 0.001), followed by inhaled corticosteroid (ICS) plus long acting beta-2 agonist (LABA) (Group A to D, n = 28 \[19.9%\], n = 122 \[24.3%\], n = 21 \[30.0%\], and n = 189 \[28.5%\]; *P* \< 0.001) ([Table 3](#t3){ref-type="table"}).

###### Medications of the COPD subjects according to the GOLD group A to D at inclusion
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  Medication^\*^                              No. (%) of patients   *P* value                             
  ------------------------------------------- --------------------- ------------ ----------- ------------ ----------
  LAMA                                        68 (48.2)             204 (40.6)   29 (41.4)   227 (34.2)   \< 0.001
  LABA                                        18 (12.8)             47 (9.4)     6 (8.6)     33 (4.8)     \< 0.001
  ICA + LABA                                  28 (19.9)             122 (24.3)   21 (30.0)   189 (28.5)   \< 0.001
  ICA + LABA + LAMA                           18 (12.8)             74 (14.7)    18 (25.7)   153 (23.0)   \< 0.001
  PDE4 Inhibitor                              2 (1.4)               5 (1.0)      2 (2.9)     35 (5.3)     \< 0.001
  Xanthine oxidase inhibitor (Theophylline)   22 (15.6)             107 (21.3)   10 (14.3)   141 (21.3)   \< 0.001
  Oral beta 2 agonist                         3 (2.1)               17 (3.4)     2 (2.9)     38 (5.7)     \< 0.001

\*Multiple responses for medication. COPD, chronic obstructive pulmonary disease; GOLD, global initiative for chronic obstructive lung disease; LAMA, long acting muscarinic antagonist; LABA, long acting beta-2 agonist; ICA, inhaled corticosteroid; PDE4 inhibitor, phosphodiesterase 4 inhibitor.

Comorbidities
-------------

The most common comorbidities among the study patients were counted hypertension (n = 323, 37.7%), depression (207, 23.6%), diabetes mellitus (139, 14.8%), GERD (83, 9.5%), coronary heart disease (43, 4.9%), heart failure (32, 3.7%), and peripheral vascular disease (15, 1.7%) ([Table 4](#t4){ref-type="table"}).

###### Comorbidities of the total COPD subjects at inclusion
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  Co-morbidity                       No.   (%)
  ---------------------------------- ----- --------
  Hypertension                       323   (37.7)
  Diabetes mellitus                  139   (14.8)
  Coronary heart disease             43    (4.9)
  Heart failure                      32    (3.7)
  Gastro Esophageal Reflux Disease   83    (9.5)
  Osteoporosis                       28    (3.2)
  Peripheral vascular disease        15    (1.7)
  Depression                         207   (23.6)

COPD, chronic obstructive pulmonary disease.

Correlation between disease severity (global initiative for chronic obstructive lung disease 2011 criteria) and symptom scores
------------------------------------------------------------------------------------------------------------------------------

[Table 5](#t5){ref-type="table"} shows the Spearman's rank correlation coefficients (R^2^) for GOLD group and symptom scores (mMRC, CAT, SGRQ-C total, and 6MWD). GOLD groups (A to D) were significantly correlated with mMRC (R^2^ 0.42, *P* \< 0.001), CAT (R^2^ 0.49, *P* \< 0.001), and SGRQ-C (R^2^ 0.45, *P* \< 0.001). The relationship between GOLD group 6MWD was significant but weak and showed a negative correlation (R^2^ −0.16, *P* \< 0.001).

###### Spearman's rank correlations coefficients between GOLD group and symptom score parameters including mMRC, CAT, SGRQ-C total and 6 minutes walk distance test
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  GOLD Group   mMRC (n = 920)   CAT (n = 882)   SGRQ-C (n = 917)   6MWD (n = 728)                             
  ------------ ---------------- --------------- ------------------ ---------------- ------ ---------- ------- ----------
  A to D       0.42             \< 0.001        0.49               \< 0.001         0.45   \< 0.001   -0.17   \< 0.001

GOLD, global initiative for chronic obstructive lung disease; mMRC, modified Medical Research Council dyspnea scale; CAT, COPD assessment test; SGRQ-C, St. George's respiratory questionnaire; 6MWD, six minutes walk distance test.

DISCUSSION
==========

The most prominent characteristic of the KOCOSS cohort is that it is composed of a relatively greater number of patients with early COPD (mean post bronchodilator FEV~1~ 55.8%) compared to other large cohorts, such as the genetic epidemiology of COPD cohort (COPDGene, mean FEV~1~ 48.3%) and the evaluation of COPD longitudinally to identify predictive surrogate endpoints cohort (ECLIPSE, mean FEV~1~ 48.9%) ([@r14],[@r15]). In line with this, the mean number of exacerbations during the year prior to enrolment was lower in our cohort than in the ECLIPSE cohort (0.6 vs. 0.9) ([@r14],[@r15]). The patients included in another large cohort study, the subpopulations and intermediate outcome in COPD study (SPIROMICS) had higher FEV~1~ values at enrollment, which may be a reflection of the different inclusion criteria for SPIROMICS (FEV~1~/FVC \< 0.7 and \> 20 pack years smoking history regardless FEV~1~) ([@r13]). It is well known that FEV~1,~ alone cannot capture the complexity of COPD to an adequate degree for prediction of exacerbation or disease progression, but it can be useful for interpreting discrepancies between the studies. The differences may also be partly due to differences among populations in terms of willingness to participate in clinical research. Another large cohort study in Korea, named Korean Obstructive Lung Disease (KOLD) showed relatively higher FEV~1~ (52.0% ± 19.4%) compared to other studies but still lower than our study even though they included asthma, and other obstructive lung disease for better understanding of COPD heterogeneity ([@r16],[@r17]). As mentioned above, we wanted to know the natural courses of COPD, excluding other causes of obstructive lung disease, in priority for early COPD. In this study, only the preliminary data analysis was done. But, future work, we could verify differences with other large cohort studies.

The relatively poor correlation between GOLD group and the 6MWD test results and the better correlation between the other symptom scores (mMRC and CAT) and the SGRQ-C and GOLD group in our result are supported by findings for the ECLIPSE cohort ([@r15],[@r18]). The multinational ECLIPSE cohort is a well-characterized group of patients with clinically stable moderate to severe COPD ([@r15],[@r18]). The determinants of 6MWD are multifactorial and include both physical (pulmonary and non-pulmonary) and psychological factors ([@r18]). Favorable exercise capacity among patients with early-stage COPD in our cohort might also have affected the 6MWD result. We expect to examine these hypotheses in greater detail during the ten-year longitudinal follow-up of the KOCOSS cohort.

The Canadian cohort obstructive lung disease (CanCOLD) study is another large cohort study that aims to develop and validate a practical risk index for COPD that predicts the clinical course in a primary care setting ([@r19]). Even in large-scale, well designed studies such as CanCOLD, evaluations focusing on each GOLD group, has the potential for ambiguous results because of using different classification compared with GOLD, a limited (3-year) follow-up period, and the primary care setting. As mentioned, the KOCOSS cohort is to be followed for 10 years, and we anticipate that this will help to further elucidate the clinical course of COPD, particularly after diagnosis at an early stage, which should provide a better chance of reducing damage to the lungs.

The inclusion of a larger number of patients with early COPD in KOCOSS as compared to the other large cohort studies (ECLIPSE, SPIROMICS, CanCOLD, and COPDGene) may provide more information about the characteristics of patients with early COPD within the classic definition of COPD. Our preliminary data will allow follow-up for improved quality of life and symptom scores after treatment started according to the GOLD guideline, especially for patients with mild to moderate COPD (data not shown). Furthermore, considering heterogeneity of COPD, results derived from a large, 45-center, well-characterized population of individuals with COPD diagnosed by pulmonary specialists and covering all areas in Korea should allow generalization of our results. The next study of the KOCOSS cohort is focused upon longitudinal changes and natural course of the COPD, including COPD in an at-risk population in an outpatient setting. We expect that it will be an important step toward identifying important variables for tailoring individualized treatment plans before and after the diagnosis of COPD.

Regardless of COPD stage, co-morbid conditions are common and are of importance in COPD since they are frequent and they affect prognosis and the costs ([@r20]). However, quantifying their burden is difficult ([@r21]). One study that evaluated data from COPD patients in the Korean Health Insurance Review and Assessment Service (KHIRA) database reported that hypertension, diabetes, ischemic heart disease, and osteoporosis as the leading comorbidities in COPD patients ([@r22]). This might be because an operational definition was used to extracting data on COPD patients from the KHIRA database. It is also possible that the somewhat higher rate of comorbidities in our study is associated with cases of hospital-diagnosed COPD and worse prognosis in the end. However, there are no tools for evaluation of these associations, although one study has shown that data from two large multicenter cohort studies (COPDGene and SPIROMICS), it is possible to formulate a simplified score to quantify comorbidity, which provided a more thorough understanding of the risk in terms of patient-centered outcomes ([@r23]). These results were derived from self-reported comorbidities without objective evaluation of these comorbidities, and severity was not reported. This situation is similar to the situation in our present study. We will need to perform additional studies to better understand the associations between the comorbidities and prognosis of COPD at each level of COPD severity. More thorough evaluation and management will also be needed for these purposes.

Of note, depressive disorders were common (23.6%) in our study compared to the KHIRA data (9.0%) ([@r22]). In line with our study, KOLD data also showed higher prevalence of depression among COPD patients (191/803, 23.8%) and depression was well correlated with CAT score ([@r16]). Even that higher prevalence of depression, the treatment or research on mental health of COPD has been insufficient. Recently, cognitive behavioral therapy was approved in a large randomized controlled trial for COPD subjects ([@r23]). Pharmacological intervention such as benzodiazepine and antidepressant was also commonly used to treat anxiety in COPD ([@r24]). We suggest that, depression should be also evaluated at the time of diagnosis of COPD and should be controlled actively with individual aspects. That will be expected to be associated with quality of life improvement and better outcome for COPD subjects by checking-up during its early stage and consistent management ([@r23],[@r24]). Further large randomized study will be needed.

Finally, with regard to treatment options, in our cohort, LAMA and ICS plus LABA were the most commonly used drugs. However, data extracted from the KHIRA records showed that methylxanthines and systemic corticosteroids were more commonly prescribed than LAMA or ICS plus LABA ([@r25]). There are several possible reasons for this. Physicians at primary and secondary facilities may prefer prescribing oral medications rather than inhalers, and the KHIRA database may include more patients who visited such centers. Furthermore, there may be patients who prefer oral medications. Treatment trends have also changed over time, and KHIRA data were compiled from 2006 to 2008, while our data collection took place from 2011 to 2014. A major challenge of KOCOSS will be maintaining long-term follow-up with the study participants.

Loss to follow-up is problematic in most cohort studies and often leads to bias. Although guidelines suggest acceptable follow-up rates, the authors are unaware of studies that have tested the validity of these recommendations. We plan to make every effort to reduce follow-up loss by close contact with each patient by scheduling periodic visits and phone calls from the clinical research coordinator and by forming a good rapport with hospitalized patients.

In conclusion, the KOCOSS is the first large cohort study that has the primary objective of describing the features of patients with COPD in each of the GOLD subtypes throughout all of Korea. Moving forward, through inclusion in future work of individuals who are at risk for COPD and healthy controls, we anticipate that our cohort study will be able to define predictive or surrogate markers of disease progression, including annual decline of FEV~1~, and analyze medical care cost, medical resource use, burden and to identify novel strategies for individualized treatment options.
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